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Epstein-Barr virus (EBV) is a probably the most effective and successful human virus, infecting more than 
90% of the world’s adult population. As with the other members of the herpesvirus family, EBV establishes 
latent infection in its host and persists life-long. EBV infection is generally harmless in children but can 
cause infectious mononucleosis (IM) in young adults. EBV is associated with a number of human 
malignancies including Burkitt’s lymphoma (BL), Hodgkin’s lymphoma (HL), nasopharyngeal carcinoma 
(NPC), nasal T/NK lymphoma (NL), peripheral T cell lymphoma, gastric carcinoma, and 
lymphoproliferative diseases in immunocompromised patients. A compromised immune system and an 
aberrant EBV latent gene expression are thought to be important players in the aetiology of EBV 
malignancies. EBV is one of the most potent transforming agents in vitro and immortalizes B cells into 
lymphoblastoid cell lines (LCLs). 
Latent membrane protein 1 (LMP1) is the main EBV oncogene, which is critically involved in 
immortalisation and proliferation of LCLs, and is associated with most EBV malignancies. LMP1 functions 
as a constitutively active tumour necrosis factor receptor (TNFR) and upregulates anti-apoptotic and pro-
survival proteins through the activation of cellular signalling pathways. Thus, inappropriate expression of 
LMP1 is probably a central process in EBV associated tumourigenesis. The aim of this PhD project was to 
delineate the regulation of LMP1 gene expression in response to cellular factors.    
The LMP1 protein expression is regulated differently according to the expression pattern of the other 
EBV latent proteins as well as the cell type in which it is expressed in. In latency III infected B cells all of 
the EBV latent proteins are expressed, and LMP1 expression is driven by the viral transcription factor 
EBNA2. The EBNA2 protein lacks DNA binding ability itself, and requires cellular factors (adaptors) to be 
recruited to promoters. In latency II cells that represent most EBV tumours and different cell-type hosts, a 
more limited set of EBV latent proteins are expressed, and LMP1 expression occurs in the absence of 
EBNA2. Regardless of the mode of expression and cell type, LMP1 transactivation is critically dependent 
on cellular proteins.  
In the course of this investigation, a new EBNA2 adaptor was identified that bound an AP-2 site in the 
LMP1 promoter and mediated the relief of promoter repression and activation of the LMP1 promoter.  
We also report EBNA2-independent upregulation of the LMP1 promoter in response to upregulation of 
the p38 kinase pathway. The p38 signalling pathway activates the ATF1-CREB heterodimer that has been 
previously shown as an activator of LMP1 transcription. The binding of ATF1-CREB to a CRE site is a 
central event in LMP1 regulation both in the presence and absence of EBNA2. 
 Additionally, we showed the presence of a mutation in the LMP1-CRE site of the P3HR1 EBV variant. 
This mutation led to a reduced binding efficiency of ATF1-CREB to the CRE site and a two fold reduction 
of LMP1 promoter activity. This finding together with reports from other groups indicate that sequence 
variations in the CRE site of LMP1 are evolutionary, selected probably to modulate the expression levels 
of the protein.  
Our results also indicate that the NF-κB dimers, p50-p65 and p50-p50, bind an NF-κB site in the LMP1 
promoter and activate transcription independently of EBNA2. The EBNA2-independent activation of 
LMP1 transcription by NF-κB suggests that this signalling pathway may play a role in LMP1 activation in 
latency II infected B cells. Since the NF-κB pathway is activated by LMP1, a positive autoregulatory loop 
in LMP1 activation may exist. The positive autoregulation of LMP1 is supported by reports from other 
groups. 
Finally, we showed that histone acetylation and modulation of the chromatin structure of the LMP1 
promoter are involved in the activation of LMP1 transcription. We hypothesise a model whereby the 
EBNA2 is recruited through interaction with several EBNA2 adaptors at the promoter and mediates 
activation. Alternatively, several transcriptional activators such as NF-κB factors and ATF1-CREB bind the 
promoter in the absence EBNA2 and cooperatively activate the promoter. In both cases factor-binding to 
the promoter leads to the recruitment of histone acetylases and chromatin remodelling enzymes to the 
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